Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
61 studies found for:    Holden Comprehensive Cancer Center | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
Holden Comprehensive Cancer Center | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme
Condition: Glioblastoma Multiforme
Interventions: Drug: Temozolomide;   Radiation: radiation therapy;   Drug: Ascorbic Acid
2 Not yet recruiting Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
Conditions: Neuroendocrine Tumor, Malignant;   Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
Interventions: Drug: 90Y-DOTA-3-Tyr-Octreotide;   Drug: 131I-MIBG
3 Recruiting Pharmacological Ascorbate for Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Ascorbic Acid
4 Recruiting Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML
Condition: Acute Myeloid Leukemia
Intervention: Drug: Lovastatin and Cytarabine
5 Recruiting Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma
Conditions: Pancreatic Ductal Adenocarcinoma;   Sarcoma
Interventions: Drug: Decitabine;   Drug: Gemcitabine
6 Recruiting Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma
Conditions: Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage II Grade 1 Contiguous Follicular Lymphoma;   Stage II Grade 1 Non-Contiguous Follicular Lymphoma;   Stage II Grade 2 Contiguous Follicular Lymphoma;   Stage II Grade 2 Non-Contiguous Follicular Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab;   Radiation: Yttrium Y-90 Ibritumomab Tiuxetan
7 Not yet recruiting A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Cancer of Pancreas;   Cancer of the Pancreas;   Neoplasms, Pancreatic;   Pancreas Cancer;   Pancreas Neoplasms;   Adenocarcinoma
Interventions: Drug: Gemcitabine;   Drug: nab-paclitaxel;   Drug: Ascorbic Acid
8 Not yet recruiting A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
Conditions: Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer;   Nonsmall Cell Lung Cancer;   Non-Small-Cell Lung Carcinoma;   NSCLC
Interventions: Drug: Radiation Therapy;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Ascorbic Acid
9 Not yet recruiting Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer
Conditions: Early-Stage Breast Carcinoma;   Estrogen Receptor Negative;   Estrogen Receptor Positive;   Grade 2 Invasive Breast Carcinoma;   Grade 3 Invasive Breast Carcinoma;   HER2/Neu Negative;   HER2/Neu Positive
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Retinoid 9cUAB30;   Procedure: Therapeutic Conventional Surgery
10 Recruiting Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
Conditions: Aggressive Non-Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Enteropathy-Associated T-Cell Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Mediastinal (Thymic) Large B-Cell Lymphoma;   Nasal Type Extranodal NK/T-Cell Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Primary Cutaneous Anaplastic Large Cell Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Small Lymphocytic Lymphoma;   Subcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions: Dietary Supplement: Cholecalciferol;   Other: Laboratory Biomarker Analysis
11 Recruiting Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)
Conditions: Infection;   Bone Neoplasms
Interventions: Drug: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen;   Drug: 5-Days Prophylactic Cefazolin* Antibiotic Regimen
12 Recruiting A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)
Conditions: Refractory Diffuse Large B Cell Lymphoma;   Refractory Primary Mediastinal B Cell Lymphoma;   Refractory Transformed Follicular Lymphoma;   Relapsed/Refractory Transplant Ineligible Diffuse Large B Cell Lymphoma;   Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma;   Relapsed/Refractory Transplant Ineligible Transformed Follicular Lymphoma
Intervention: Biological: KTE-C19
13 Recruiting Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
Condition: Melanoma
Interventions: Drug: TAK-580;   Drug: TAK-202;   Drug: vedolizumab;   Drug: nivolumab;   Drug: ipilimumab
14 Recruiting Study of Blood Samples From Newborns With Down Syndrome
Condition: Leukemia
Interventions: Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study
15 Recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Conditions: Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IB Squamous Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIA Squamous Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIB Squamous Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Squamous Cell Lung Carcinoma
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
16 Recruiting A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: SGN-CD352A
17 Recruiting Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Condition: Salivary Cancer
Intervention: Drug: enzalutamide
18 Recruiting Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
Conditions: Lymphoma;   Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure;   Other: informational intervention
19 Recruiting Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma
Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
20 Recruiting Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Neoplasm;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage III Fallopian Tube Cancer;   Stage III Ovarian Cancer;   Stage III Primary Peritoneal Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Drug: Ruxolitinib Phosphate;   Procedure: Therapeutic Conventional Surgery

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.